These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 16758261)

  • 1. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
    Müller T; Kuhn W
    Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
    Müller T; Woitalla D; Hauptmann B; Fowler B; Kuhn W
    Neurosci Lett; 2001 Jul; 308(1):54-6. PubMed ID: 11445284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
    Müller T; Woitalla D; Muhlack S
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):627-33. PubMed ID: 21533995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
    Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ
    J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
    Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
    Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
    Muhlack S; Herrmann L; Salmen S; Müller T
    J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
    Guay DR
    Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tolcapone in the treatment of Parkinson's disease.
    Leegwater-Kim J; Waters C
    Expert Rev Neurother; 2007 Dec; 7(12):1649-57. PubMed ID: 18052761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
    Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
    Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
    Borges N
    Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of COMT inhibition on levodopa pharmacology and therapy.
    Goetz CG
    Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.